What’s the current market cap for Boston Scientific stock?

Boston Scientific (BSX) has a market cap of $71B as of June 03, 2026.

What is the P/E ratio for Boston Scientific stock?

The price to earnings (P/E) ratio for Boston Scientific (BSX) stock is 19.95 as of June 03, 2026.

Does Boston Scientific stock pay dividends?

No, Boston Scientific (BSX) stock does not pay dividends to its shareholders as of June 03, 2026.

When is the next Boston Scientific dividend payment date?

Boston Scientific (BSX) stock does not pay dividends to its shareholders.

What is the beta indicator for Boston Scientific?

Boston Scientific (BSX) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Boston Scientific stock | $BSX Share Price

About Boston Scientific

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.

Ticker

$BSX

Sector

Health

Primary listing

NYSE

Employees

59,000

Headquarters

Marlborough, United States

Website

www.bostonscientific.com

BSX Metrics

BasicAdvanced

$71bn

19.95

$2.39

0.62

-

What the Analysts think about BSX

Analyst ratings (Buy, Hold, Sell) for Boston Scientific stock.

Bulls say / Bears say

Boston Scientific agreed to acquire Penumbra for $14.5 billion on January 15, 2026—its second-largest takeover—to re-enter the neurovascular market and broaden its cardiovascular device portfolio, positioning the company for accelerated growth in high-margin segments. (Reuters)

The FDA granted 510(k) clearance for Boston Scientific’s Asurys™ Fluid Management System on March 30, 2026, enabling U.S. launch of an advanced urology irrigation and pressure-management device that could drive material growth in its urology segment. (Reuters)

On May 18, 2026, Boston Scientific invested $1.5 billion for a 34% stake in MiRus LLC—securing an option to acquire its balloon-expandable TAVR technology—re-establishing Boston’s presence in the high-growth transcatheter heart valve market. (Reuters)

Boston Scientific’s modest 2026 revenue growth and profit guidance—projecting flat to low-single-digit top-line gains and earnings slightly below consensus—announced on February 4, 2026, triggered an 11% premarket share decline and highlights near-term growth constraints. (Reuters)

On April 22, 2026, Boston Scientific cut its full-year 2026 revenue and profit forecasts, citing headwinds in its electrophysiology, Watchman and urology businesses, underscoring persistent segmental challenges despite recent innovation. (Reuters)

Shares plunged to a two-year low on May 27, 2026, after management warned of softer uptake for its Watchman left atrial appendage closure device, signaling weakening demand in its core cardiology franchise. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 1 Jun 2026.

BSX Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

BSX Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

BSX News

AllArticlesVideos

Why These Three Big Buybacks Are Sending Very Different Signals to Investors

MarketBeat·2 days ago

Boston Scientific Advances Coronary Calcium Treatment With Positive Trial Results

Benzinga·2 weeks ago

Boston Scientific Targets Growing Aortic Stenosis Market With $1.5 Billion Deal

Benzinga·2 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.